Gland Pharma Delivers Robust Q4 Surge With Record Profit, Strong CDMO Momentum

Nikunj Parikh May 15, 2026 400 Views

Gland Pharma reported a strong finish to FY26, with record quarterly revenue, sharply higher profitability and a higher contribution from its CDMO and complex injectables portfolio, underlining its position in the global injectable pharmaceuticals market.

Gland Pharma has posted a healthy March quarter, riding on double‑digit growth in its US and Europe businesses, strong CDMO traction and operating leverage gains. The company also rewarded shareholders with a generous dividend proposal for FY26.

Earnings Snapshot: Revenue, Profit And Margins

Consolidated revenue from operations in Q4 FY26 rose 22% year-on-year to 17,428 million rupees, while adjusted net profit nearly doubled to 3,667 million rupees, up 97%. Adjusted EBITDA grew 51% to 5,244 million rupees, with margins expanding to 30% from 24% a year ago.

Full-Year FY26 Performance And Dividend

For FY26, consolidated revenue from operations increased 14% to 64,307 million rupees, with adjusted PAT up 50% at 10,455 million rupees and adjusted EBITDA margin improving to 26%. The board has recommended a final dividend of 20 rupees per equity share for FY26, subject to shareholder approval.

Business Mix, Markets And Growth Drivers

CDMO contributed 46% of consolidated revenues and grew 36% year-on-year in Q4 FY26, while the base business delivered 22% revenue growth with a 41% adjusted EBITDA margin. The US remained the largest market with Q4 FY26 revenue of 9,807 million rupees (up 24%), followed by Europe at 3,814 million rupees (up 36%).

Innovation Pipeline And R&D Investments

R&D spend stood at 506 million rupees in Q4 FY26 and 2,230 million rupees in FY26, focused on complex injectables, GLP‑1s, insulin analogs and ready‑to‑use infusion bags. The company launched five molecules in the US in Q4, filed eight ANDAs and received 11 approvals, taking cumulative US ANDA filings to 388, with 337 approved and 51 pending.

Key highlights

Q4 FY26 revenue from operations: 17,428 million rupees, up 22% year-on-year
Q4 FY26 consolidated adjusted PAT: 3,667 million rupees, up 97% year-on-year
FY26 revenue from operations: 64,307 million rupees, up 14% year-on-year
CDMO share of Q4 FY26 revenue: 46%, CDMO revenue growth 36% year-on-year
Base business Q4 FY26 adjusted EBITDA margin: 41%; consolidated Q4 margin: 30%
Total FY26 R&D spend: 2,230 million rupees, about 4% of base business revenue in Q4
US Q4 FY26 revenue: 9,807 million rupees; Europe Q4 revenue: 3,814 million rupees
Eight ANDAs filed and 11 approved in Q4 FY26; 31 products launched in the US during FY26
Final dividend recommended: 20 rupees per equity share for FY26